Rigel Pharmaceuticals, Inc.

As of June 30, 2026, Rigel Pharmaceuticals, Inc. carries a market capitalization of 648.60M, placing it among publicly traded companies globally. Its enterprise value stands at 600.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Rigel Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Rigel Pharmaceuticals, Inc. has 18.65M shares outstanding.

As of June 30, 2026, Rigel Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 2.26. The price-to-sales ratio is 2.63, and the price-to-book ratio stands at 1.74.

As of June 30, 2026, Rigel Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 7.64 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.48 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 7.88 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 600.12M versus a market cap of 648.60M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Rigel Pharmaceuticals, Inc. maintains a current ratio of 1.94, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 9.39, indicating elevated leverage, while an interest coverage ratio of 15.45 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Rigel Pharmaceuticals, Inc. posted a return on equity (ROE) of 126.90, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 88.46, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.41M in revenue per employee across its workforce of 171.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.92 indicates how many times Rigel Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Rigel Pharmaceuticals, Inc. recorded an income tax benefit of -206.86M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 74.90M, leaving 281.77M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 41.02, while the 200-day moving average is 31.92.

Over the twelve months ended June 30, 2026, Rigel Pharmaceuticals, Inc. generated 242.27M in revenue and converted that into 281.77M in net income, yielding earnings per share of 14.41. EBITDA reached 78.51M, while operating income came in at 76.19M.

As of June 30, 2026, Rigel Pharmaceuticals, Inc. holds 83.44M in cash and equivalents against 34.97M in total debt, resulting in a net debt position of -18.89M. Total book value stands at 372.37M, with working capital of 78.73M providing operational flexibility.

Rigel Pharmaceuticals, Inc. produced 69.49M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled 69.49M - equivalent to 3.80 per share.

Over the twelve months ended June 30, 2026, Rigel Pharmaceuticals, Inc. posted a gross margin of 91.39, reflecting its pricing power and cost economics. The operating margin of 31.45 and net profit margin of 116.30 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 10.22, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.09, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Rigel Pharmaceuticals, Inc. shareholders.

Rigel Pharmaceuticals, Inc.'s most recent stock split took place on June 27, 2024 with a 10:1 split ratio.

As of June 30, 2026, Rigel Pharmaceuticals, Inc. has an Altman Z-Score of 2.95, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.